Hemophilia & Bleeding Disorders Flashcards

1
Q

hemophilia - overview

A

*can be congenital or acquired
*inability to from adequate complete clots due to specific clotting factor deficiency:
-mechanism: impaired/dysfunctional thrombin burst
*most commonly an X-linked recessive disorder, so affects males predominantly (females are often symptomatic carriers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

types of hemophilia

A

*factor VIII deficiency = classic hemophilia = hemophilia A
*factor IX deficiency = Christmas disease = hemophilia B
*factor XI deficiency (occasionally called hemophilia C)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

coagulation mnemonics

A

*the PT (extrinsic) and the PTT (intrinsic) pathways meet at factor X because “X” marks the spot
*factor V is a cofactor for factor X, and you can remember this because V fits into the notch of X
*factor Xa converts prothrombin into thrombin
*thrombin converts the soluble molecule fibrinogen into a fibrin clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what clotting factor should we investigate if ONLY the PT is prolonged

A

factor VII deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what clotting factor should we investigate if ONLY the PTT is prolonged

A

deficiencies of factors 12, 11, 9, or 8 (XII, XI, IX, or VIII)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what clotting factor should we investigate if BOTH the PT and PTT are prolonged

A

most likely, factor X deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

clotting factor deficiencies that are clinically significant

A

*deficiencies of factors XI, IX, VIII, VII, X, V, prothrombin, and fibrinogen are clinically significant
*inhibitors of these factors are clinically significant for bleeding

note - deficiency of factor XII, and the presence of the lupus anticoagulant, are not clinically significant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

hemophilia inheritance pattern

A

*X-linked recessive
*affects males predominantly (can occur in females though)
*can skip generations
*30% spontaneous (de novo) mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

hemophilia - genetics

A

*factor VIII (hemophilia A) and factor IX (hemophilia B) genes are located near the top of the long arm of the X chromosome
*point mutations are the most common, but different mutation known to have different clinical phenotypes
*result in either case is absence of or low level of FVIII or FIX activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hemophilia - female carriers

A

*majority of symptomatic individuals are male
*heterozygote females can be “symptomatic carriers” with bleeding tendencies and pattern most centered around baseline levels
*lyonization effect or double heterozygote inheritance can result in lower residual activity and clinically relevant bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

hemophilia - clinical manifestations

A

*joint bleeds -> target joints (most relevant)
*deep muscle bleeds
*hematomas
*post-surgery/post-trauma
*dental extractions
*intracranial hemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

hemophilia - severity of disease

A

<1% clotting activity = severe; sx in early childhood & spontaneous bleeds

1-5% clotting activity = moderate; bleeding after minor trauma or surgery; may be spontaneous

5-30% clotting activity = mild; only bleed after trauma or surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

hemophilic arthropathy

A

*recurrent bleeds in joints
-inflammation, bony destruction, acute pain
-chronic pain (arthritis)
*decreased range of motion
*long-term disability, psychosocial consequences

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

development of hemophilic arthropathy

A

repeated joint bleeds → hemophilic arthropathy → pain and functional impairment

*proliferation of capillaries; synovial cell hyperplasia
*inflammatory cells infiltrate joint space → destruction of cartilage → synovial proliferation into joint space, burrowing into bone and covering cartilage → destruction of joint!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

hemophilia - intramuscular/soft tissue bleeding

A

areas of greatest concern:
*face, neck, mouth, eye
*palm of hand, wrist
*calf
*thigh or groin
*hip or shoulder
*hematuria, GI tract bleeding

note - bleeding of muscles or soft tissues occur less frequently than joint bleeds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

hemophilia A - lab findings

A

*ELEVATED PTT
*normal PT
*normal platelet count
*normal PFA-100

factor VIII assay:
severe = < 1%
moderate = 1-5%
mild = 6-30%

17
Q

hemophilia B - overview

A

*factor IX deficiency
*less common than hemophilia A
*X-linked mutation/deletion in factor IX gene (first described in Christmas family)

18
Q

hemophilia B - lab findings

A

*ELEVATED PTT
*normal PT
*normal platelet count
*normal PFA-100

19
Q

treatment of hemophilia

A

*plasma-derived factor concentrates:
-start with a pool of carefully screened donor plasma
-viral inactivation procedures (pasteurization, solvent-detergent treatment, ultrafiltration) are effective against HIV and hepatitis viruses

*recombinant human factor concentrates:
-purified from transfected mammalian cell lines
-no further viral attenuation needed

note: PROPHYLAXIS is KEY!

20
Q

complications of hemophilia treatment

A

*development of inhibitors (allo-antibodies) [more common in hemophilia A]
*infections: HBV, HBC, HIV, CMV, parvo B19

21
Q

acquired hemophilia (AHA)

A

*development of anti-Factor VIII antibodies
*NO preexistent congenital FVIII deficiency
-uncommon, occurs in older adults, 50% with underlying autoimmune disease
*presentation: prolongation of aPPT, large ecchymotic lesions, usually muscle bleeds

22
Q

emicizumab (hemophilia therapy)

A

*normally, FVIII acts as a bridge to bring FIX near FX
*emicizumab is an antibody that MIMICS the activity of FVIII and performs the function of bringing together FIX and FX!!

23
Q

gene therapy for hemophilia

A

*bioengineered particle with factor VIII gene
*target organ = liver
*clinical outcome: patient begins making factor VIII

24
Q

von Willebrand’s Disease - inheritance pattern

A

AUTOSOMAL DOMINANT (but clinical variability, sometimes autosomal recessive)

25
Q

von Willebrand’s Disease - overview

A

*most common bleeding disorder
*heterogeneous group of inherited or acquired bleeding disorders
*different types, including both quantitative (amount) and qualitative (function) deficiencies

26
Q

von Willebrand’s Disease - symptoms

A

*menorrhagia (heavy menstrual cycle)
*epistaxis
*gingival bleeding
*hemorrhage after dental extraction

note - mucous membranes are the most common bleeding sites in patients with von Willebrand’s Disease

27
Q

von Willebrand’s Disease - lab findings

A

*normal PT
*prolonged or normal PTT
*vWF LOW
*factor VIII may be moderately reduced
*normal factor IX

28
Q

how does vWF work

A

*factor VIII and vWF form a complex, where vWF protects FVIII from degradation
*platelets bind vWF via GpIb to subsequently bind collagen on injured endothelium

29
Q

treatment of von Willebrand’s Disease

A

*DDAVP:
-synthetic analog of ADH L-vasopressin
-intranasal spray or intravenous
-releases stored vWF from endothelial cells

*humate-P and other products:
-factor VIII concentrate containing BOTH vWF and factor VIII
-2:1 concentrate of vWF to VIII